Skip to content
by Legal Desire
8 November 2025

Latham & Watkins Advises on Halozyme Therapeutics’ Convertible Senior Notes Offerings Totaling US$1.3 Billion

Advising firms

Deal team

17 lawyers named
LawyerFirmSeniorityPracticeOffice
Greg Rodgers Lead Latham & Watkins LLP Partner Capital Markets Not stated
Andrew Blumenthal Lead Latham & Watkins LLP Partner Capital Markets Not stated
Ian Lachow Latham & Watkins LLP Associate Capital Markets Not stated
Steve Hess Latham & Watkins LLP Associate Capital Markets Not stated
Cheston Larson Latham & Watkins LLP Partner corporate Not stated
Michael Sullivan Latham & Watkins LLP Partner corporate Not stated
Sterling Swift Latham & Watkins LLP Associate corporate Not stated
Samantha Wang Latham & Watkins LLP Associate corporate Not stated
Reza Mojtabaee-Zamani Latham & Watkins LLP Partner derivatives Not stated
Sloan Ungerman Latham & Watkins LLP Associate derivatives Not stated
Daniel Weiss Latham & Watkins LLP Associate derivatives Not stated
Bora Bozkurt Latham & Watkins LLP Partner tax Not stated
Jack Santoro Latham & Watkins LLP Associate tax Not stated
Chad Jennings Latham & Watkins LLP Counsel FDA regulatory Not stated
Betty Pang Latham & Watkins LLP Partner healthcare regulatory Not stated
Darryl Steensma Latham & Watkins LLP Counsel intellectual property Not stated
Kristina Funahashi Latham & Watkins LLP Associate intellectual property Not stated

14 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 1.30bn (US$1.3 Billion)
What the figure measures
Issue size
Client
initial purchasersUnderwriters
Counterparties
Halozyme Therapeutics, Inc. (Issuer)